35p chat line
Trying to get my entry price is like pulling teeth!I've picked up another 5k over the last 2 days and have another 15k in orders sitting there.If Mylan get FDA approval for their version of generic Advair which is due to heard next month, I doubt that there will be much left of the Advair market for Hikma/VEC to aim at by the time they might eventually get the nod in around 18 months time.The race will have been well and truly lost by then.
22p connection fee applies to all non-inclusive calls to 01, 02 and 03.
All VEC can do is hope that the FDA issue another refusal, if they do it might give the VEC share price a bit of a boost up... Vectura Group Vectura Group (VEC) is a leader in the development of respiratory products, including treatments for asthma and Chronic Obstructive Pulmonary Disease (COPD) aka 'smoker's cough' - the fourth leading cause of death worldwide with increasing prevalence particularly in the elderly.
but if Mylan DO get approval then I expect poor market sentiment will knock VEC's share price back again even though there's perceived to be currently nothing in it for Advair. The development of inhaled drugs requires the interplay of the following three factors: the drug, the formulation and the device; thus, it is a complex field, in which Vectura is a global leader with a very strong track record.
They then have to make a new submission when the results of the trial are known.
It normally takes around 10 months to get the results from the FDA...
It's now at 78p, due an order i forgot to delete (set a daily time limit) while in the US causing me to pick some up at 98p. If GSK are really pushing the Ellipta series - trelegy, Anoro, Breo and Incruse then any generic device will have a field day on GSK sales and forward earnings estimates. In brief, nothing new (almost), but steady as she goes, very confident going forward, and plenty expected to be reported in the interim statement in September.